Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button wuxixdc_info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Services & Solutions
Information Downloads

Poster modified on 07/05/2026

Seamless Integration of Antibody Purification and Antibody-Drug Conjugation
Traditional ADC manufacturing involves a highly complex, multi-stage workflow: antibody intermediate production, payload-linker synthesis, ADC drug substance manufacturing, and final drug product manufacturing. Manufacturing each of the 4 components—monoclonal antibodies(mAbs), payload-linkers, drug substance, drug product— demands different expertise, dedicated facilities, quality control and release. In some cases, mAb purification and conjugation processes apply redundant column purifications, resulting in a long and complicated process. This redundancy leads to inefficient operations and high manufacturing costs.

At WuXi XDC, our team has innovated and streamlined an integrated manufacturing process, which smartly combined mAb purification process and antibody-drug conjugation process, effectively reducing some redundant column and UF/DF steps. This significantly shortens development timeline, reduces the time needed for manufacturing ADC, and lowers the manufacturing cost.

 

                   

Discuss This Service Overview

To discuss the information in this service overview, please complete the form on the following page to connect with our experts.

Connect with our Experts

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?